Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas (Q42721017)

5 November 2017

title

Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas (English)

1 reference

5 November 2017

Mei Dong

1

1 reference

5 November 2017

Zhi-Qiang Ning

2

1 reference

5 November 2017

Pu-Yuan Xing

3

1 reference

5 November 2017

Jia-Lian Xu

4

1 reference

5 November 2017

Hai-Xiang Cao

5

1 reference

5 November 2017

Gui-Fang Dou

6

1 reference

5 November 2017

Zhi-Yun Meng

7

1 reference

5 November 2017

Yuan-Kai Shi

8

1 reference

5 November 2017

Xian-Ping Lu

9

1 reference

5 November 2017

Feng-Yi Feng

10

1 reference

5 November 2017

publication date

24 February 2012

1 reference

Cancer Chemotherapy and Pharmacology

5 November 2017

published in

1 reference

5 November 2017

volume

69

1 reference

5 November 2017

issue

6

1 reference

5 November 2017

page(s)

1413-1422

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-012-1847-5

5 November 2017

exact match

0 references

cites work

Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1847-5

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1847-5

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1847-5

Histone deacetylase inhibitors in lymphoma and solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1847-5

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1847-5

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1847-5

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1847-5

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1847-5

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1847-5

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1847-5

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1847-5

Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1847-5

Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1847-5

Quantitative structure-activity relationship study of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1847-5

HDAC inhibitors: clinical update and mechanism-based potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1847-5

A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1847-5

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1847-5

Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1847-5

Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1847-5

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1847-5

Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1847-5

Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1847-5

10.1007/S00280-012-1847-5

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

5 November 2017

1005492486

0 references

1 reference